In this fourth edition of Pharmazoomer, get the latest news on local production agreements, GLP-1 pills, financial operations, transactions… Dar Aldawa, Mubadala Bio, Tabuk Pharmaceuticals, Laprophan; Sothema, Avalon Pharma…
South Africa 🇿🇦
— South Africa launches CSIR FuturePharma facility to boost local pharmaceutical manufacturing FuturePharma will support the development, scale up and production of pharmaceutical technologies, helping to address a persistent challenge in the industry: translating scientific discoveries into products that can be manufactured commercially. Healthcare Middle-East and Africa
— Aspen sells menopause treatment Ovestin’s European rights for €197m Aspen expects a R2bn profit on the disposal but will retain a 10-year manufacturing and supply role Business Day (ZA)
Saudi Arabia 🇸🇦
— DKSH buys NewBridge for $390M to enter Middle East healthcare Swiss market-expansion group DKSH has agreed to acquire 100% of Dubai-based NewBridge Pharmaceuticals for an enterprise value of $390 million. NewBridge markets specialty and rare-disease medicines across 14 markets in the Middle East and North Africa (MENA), with Saudi Arabia and the United Arab Emirates among the largest. app.dealroom.co
— Jamjoom Pharma and Mubadala Bio’s Bioventure Healthcare Partner to Expand Patient Access to Ustekinumab in the UAE Jamjoom Pharma will be the exclusive commercial arm for Bioventure Healthcare’s (BVH) Ustekinumab, combining BVH’s product and supply with Jamjoom Pharma’s outreach, scale and medical education expertise. Jamjoom Pharma
— Avalon Pharma Signs International Partnership with OneSource to Expand Obesity and Metabolic Diseases Drugs in Saudi Arabia and the Region Avalon Pharma, listed on the Saudi Stock Exchange (Tadawul), continues to build its portfolio in the field of weight management and metabolic diseases, through an agreement with OneSource International. The agreement includes the rights to register and market an injectable product in Saudi Arabia and in markets in the Middle East and North Africa. ae.linkedin.com
— Tabuk Pharma and Sandoz Announce Strategic Partnership to Support the Localization of Specialized Medicines in Saudi Arabia Tabuk Pharma has signed a strategic partnership agreement with Sandoz, under the sponsorship of the Local Content and Government Procurement Authority (LCGPA), to support the localization of specialized pharmaceutical products in Saudi Arabia. Tabuk Pharmaceuticals
— SFDA Grants Breakthrough Designation of a Drug Targeting the Treatment of Certain Types of Cancer Under the Breakthrough Program The SFDA has announced its approval to designate a drug under the Breakthrough Medicines Program for the treatment of adult patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma whose tumors are CLDN18.2 positive and whose disease progressed during or after at least one prior therapy for locally advanced unresectable or metastatic disease. SFDA — Saudi Food and Drug Authority
Bahrain 🇧ðŸ‡
— Bahrain approves Wegovy GLP-1 pills for obesity treatment The National Health Regulatory Authority (NHRA) of Bahrain has approved Wegovy (semaglutide) pills, an oral glucagon-like peptide-1 (GLP-1) treatment for obesity, expanding access to advanced weight-management therapies in the Kingdom. gccbusinessnews.com
New! Read the full Pharmazoomer on Hexamonitor